Evaluation of Safety/Efficacy of Diagnostic Skin Test Panel and Desensitization Hormone Kit for Treatment of Premenstrual Syndrome (PMS)

E

EVE Medical Systems

Status and phase

Unknown
Phase 2

Conditions

Premenstrual Syndrome

Treatments

Drug: Skin test panel and solvent
Drug: Skin test panel and desensitization kit

Study type

Interventional

Funder types

Industry

Identifiers

NCT00873262
EVE-2008-03

Details and patient eligibility

About

The EVE-PMS technology is intended for determination of intolerance or sensitivity to sex hormones, among women suffering from severe PreMenstrual Syndrome (PMS) and desensitizes them with the relevant sex hormones in order to reduce PMS symptoms. The system includes skin testing panel for identification of hormones to which the patients might be sensitive. Tests are applied close to the ovulation period and the skin reaction is examined in 20 minutes, 48 hours and daily during the following month. Results of skin tests and patient's history will determine the eligibility of the patients to enter a desensitization protocol. During the desensitization period hormones to which the patient were found sensitive to, are injected intradermally three times (once a month) within the luteal phase in increasing doses. The end-point of the study is a statistically significant decrease, or elimination of PMS symptoms, compared to a solvent group.

Enrollment

20 estimated patients

Sex

Female

Ages

20 to 45 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Person is over the age of 20 but not older than age 45.

  2. Person is willing to participate as evidenced by signing the written informed consent form.

  3. Suffers from known dominant severe symptom of breast swelling and tenderness (level 7-10 according to standard scale of PMS symptoms severity)

  4. Other severe symptoms of Premenstrual syndrome (based on WHO and ACOG criteria). This may include one or more of PMS symptoms with level 7-10 according to standard scale of PMS symptoms severity.

  5. At work, school, home, or in daily routine, at least one of the PMS symptoms caused reduction of productivity or inefficiency

  6. At least one of the PMS symptoms caused avoidance of or less participation in hobbies or social activities

  7. At least one of the PMS symptoms interfere with relationships with others

    • Timing of PMS symptom(s): during the 14 days prior to onset of menstrual flow (rather than spotting) and up to 5 days during the menstrual flow.
    • Pattern and length of PMS symptomatic period: minimum of 2 days, up to 14 days.
    • For PMS diagnosis two out of last three consecutive menstrual cycles were monitored by daily monitoring of symptoms.
    • Timing and length of asymptomatic phase: day 6 to at least day 10 of the menstrual cycle.
    • Cyclicity - presentation of the 'off-on' phenomenon: there should be a clear shift from no PMS symptoms to PMS symptoms.
    • Reliable non hormonal contraception.

Exclusion criteria

  1. Pregnant or lactating woman
  2. Oral contraceptives during last three months, including hormonal IUD (trade name mirena).
  3. Serious health problems.
  4. Unexplained menstrual disorders.
  5. Treated by hormones (estrogen and progesterone).

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Factorial Assignment

Masking

Single Blind

20 participants in 2 patient groups, including a placebo group

Hormones
Active Comparator group
Treatment:
Drug: Skin test panel and desensitization kit
Solvent
Placebo Comparator group
Treatment:
Drug: Skin test panel and solvent

Trial contacts and locations

1

Loading...

Central trial contact

Alek Itsekson, Dr.; Yonit Bomstein, Dr.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems